EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers

Olga Morozova iD, Marina Kornilova, Olena Makarenko, Svitlana Antoniak, Mariia Liulchuk, Olga Varetska, Kostyantyn Dumchev iD

Journal of the International AIDS Society · 2024-07 · 27 (S3)

DOI: 10.1002/jia2.26319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, online erschienen am 19.07.2024. Verfasst von Olga Morozova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biological Sciences Division, Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents, Substance Abuse, Intravenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Global Fund to Fight AIDS, Tuberculosis, and Malaria, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Daily oral HIV pre‐exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) is recommended for people who inject drugs (PWID) but coverage is low. The real‐life effectiveness of PrEP among PWID is unknown as previous studies were conducted in controlled settings and mainly relied on self‐report. Analysis of PrEP metabolites—tenofovir diphosphate (TFVdp) and emtricitabine triphosphate (FTCtp)—offers an objective measure of adherence.

Methods

To analyse longitudinal patterns of PrEP adherence among PWID in Ukraine, we used data from a community‐based implementation trial conducted in Kyiv between July 2020 and March 2021 to test the efficacy of SMS reminders to improve adherence. Among 199 enrolled participants, 156 (78.4%) were retained through 6 months. Based on TFVdp/FTCtp levels assessed at 3 and 6 months, we identified groups with various adherence patterns (adherent at ≥2 doses/week, improved, worsened, non‐adherent). Correlates of adherence were analysed using multinomial logistic regression.

Results

Most participants (53.8%, n = 84/156) had no detectable metabolites at both assessments; 7.1% ( n = 11/156) were consistently taking ≥2 doses/week; 1.3% ( n = 2/156) were consistently taking ≥4 doses/week; 13.5% ( n = 21/156) exhibited improved and 21.8% ( n = 34/156) had worsened adherence at 6 compared to 3 months. “White coat compliance” (increased dosing prior to assessment) was common. Consistent adherence was associated with SMS reminders, younger age, employment, lower income, longer injection drug use duration, recent high‐risk injecting (receptive syringe sharing, using pre‐filled syringe, back‐ or front‐loading, container sharing), absence of overdose in the past 6 months, perceived HIV risk through sexual intercourse and higher PrEP self‐efficacy. Alcohol consumption was associated with inconsistent PrEP use. Groups with improved and worsened adherence did not differ.

Conclusions

Daily oral PrEP may not achieve the desired effectiveness among PWID as a standalone intervention, calling for testing of alternative PrEP formulations and innovative integrated risk reduction strategies, especially in the context of HIV epidemics associated with injection drug use in eastern Europe and central Asia and the public health crisis in Ukraine caused by the war with Russia. SMS reminders may be effective among PWID who prioritize PrEP. Our findings offer practical guidance in identifying PWID who are likely to benefit from PrEP and those who need additional support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisHIV InfectionsAnti-HIV AgentsSubstance Abuse, IntravenousDrug MonitoringHumansUkraineMaleAdultFemaleEmtricitabineMiddle AgedBiomarkersLongitudinal StudiesTenofovirYoung AdultAdministration, OralAdenineOrganophosphates

Stichwörter der Autor:innen

biomarkersdried blood spotemtricitabineemtricitabine triphosphatetenofovirtenofovir diphosphate

Substanzen

Anti-HIV AgentsEmtricitabineBiomarkersTenofovirtenofovir diphosphateAdenineOrganophosphates

Autor:innen und Institutionen

  • Biological Sciences Division, Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.
  • International Charitable Foundation "Alliance for Public Health", Kyiv, Ukraine.
  • Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.
  • Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine.

ORCID-Profile: Olga Morozova, Kostyantyn Dumchev

Förderung

  • NIAID NIH HHS
  • Global Fund to Fight AIDS, Tuberculosis, and Malaria
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Morozova, O., Kornilova, M., Makarenko, O., Antoniak, S., Liulchuk, M., Varetska, O., & Dumchev, K. (2024). Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers. Journal of the International AIDS Society, 27(S3). https://doi.org/10.1002/jia2.26319

Vancouver

Morozova O, Kornilova M, Makarenko O, Antoniak S, Liulchuk M, Varetska O, et al. Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers. Journal of the International AIDS Society. 2024;27(S3). doi:10.1002/jia2.26319

BibTeX
@article{Morozova2024,
  author = {Morozova, Olga and Kornilova, Marina and Makarenko, Olena and Antoniak, Svitlana and Liulchuk, Mariia and Varetska, Olga and Dumchev, Kostyantyn},
  title = {Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers},
  journal = {Journal of the International AIDS Society},
  year = {2024},
  volume = {27},
  number = {S3},
  doi = {10.1002/jia2.26319}
}
Kostenlos starten →